Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. - Wikidata - wikimedia - TriplyDB

Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.

Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.

http://www.wikidata.org/entity/Q31029305

about

Identification of an amyloid fibril forming peptide comprising residues 46-59 of apolipoprotein A-I Proteomics and mass spectrometry in the diagnosis of renal amyloidosis Amyloid diseases of the heart: current and future therapies Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing - a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis Structural and Functional Analysis of the ApolipoproteinA-I A164S Variant The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment.Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approach.Conformational and aggregation properties of the 1-93 fragment of apolipoprotein A-I.Amyloid nephropathy A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred.Myeloperoxidase-mediated Methionine Oxidation Promotes an Amyloidogenic Outcome for Apolipoprotein A-I.The Successful Diagnosis and Typing of Systemic Amyloidosis Using A Microwave-Assisted Filter-Aided Fast Sample Preparation Method and LC/MS/MS Analysis.Amyloidogenic Mutation Promotes Fibril Formation of the N-terminal Apolipoprotein A-I on Lipid Membranes.Cellular interaction and cytotoxicity of the iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate.Structural Stability and Local Dynamics in Disease-Causing Mutants of Human Apolipoprotein A-I: What Makes the Protein Amyloidogenic?Dual role of an N-terminal amyloidogenic mutation in apolipoprotein A-I: destabilization of helix bundle and enhancement of fibril formation.Amyloidogenic variant of apolipoprotein A-I elicits cellular stress by attenuating the protective activity of angiogenin.Proteomic typing of amyloid deposits in systemic amyloidoses.Clinical proteomics for diagnosis and typing of systemic amyloidoses.Amyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights Apolipoprotein A-I: the dual face of a protein.Heart transplantation in cardiac amyloidosis.Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study.Iowa Mutant Apolipoprotein A-I (ApoA-IIowa) Fibrils Target Lysosomes.Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature.Renal ApoA-1 amyloidosis with Glu34Lys mutation and intra-amyloid lipid accumulation.Clinical and pathologic characteristics of hereditary apolipoprotein A-I amyloidosis in Ireland.The polyphenol (-)-epigallocatechin-3-gallate prevents apoA-IIowa amyloidosis in vitro and protects human embryonic kidney 293 cells against amyloid cytotoxicity.Pathology and diagnosis of renal non-AL amyloidosis.Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein.Online registry for mutations in hereditary amyloidosis including nomenclature recommendations.Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging.Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis.Triglyceride increase in the core of high-density lipoproteins augments apolipoprotein dissociation from the surface: Potential implications for treatment of apolipoprotein deposition diseases.Effect of Phosphatidylserine and Cholesterol on Membrane-mediated Fibril Formation by the N-terminal Amyloidogenic Fragment of Apolipoprotein A-I.Epigallocatechin-3-gallate remodels apolipoprotein A-I amyloid fibrils into soluble oligomers in the presence of heparin High 99mTc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy

P2860

Q24323500-562D7220-42B9-4703-8E53-F5133A42DB94 Q26776392-FA5E89DB-33BC-4068-96DD-3F8440B3080A Q27023836-69566B67-1324-40D9-9A22-370A1E667A76 Q28116206-D0DA7EC3-90A7-4503-B87E-51E71298DBD0 Q28551157-CF4A8554-9016-4555-9667-32F713F3DB0C Q30411501-2D819639-796E-4E0B-A310-423B055B67B1 Q34499457-2EFC54BE-F9DD-4E12-9E92-114E6C12F3E3 Q34559652-4934138E-ED49-4182-BC15-D5E946FFC0F8 Q35227671-EA9F0273-C6B4-4BC5-B20E-4BF6D9A753AC Q35456927-133FD4E2-7F14-4024-8C48-D93CB0D3790A Q35536293-2D2D8801-B04F-4913-92DE-44E9D5C32C8A Q35634118-5C75F200-CADE-44F0-94F1-5BB8E293517C Q35978258-253AD840-3BA1-4CD9-815B-06020A8EBB60 Q36115813-83977263-57C6-4C25-8A9B-75FB53C00DE2 Q36553540-6A5A4A1C-E215-432A-9747-6A78C404DB32 Q36562153-8E4E5446-9EB8-46AD-A128-BB3EAD8EEE94 Q37680238-2F5F7648-E31A-4AFF-8E3B-DA01B78EC36E Q37955712-E2999EE7-F8DF-45F4-822A-D4E8A3238F2A Q38062901-BF1F4DD7-E5C8-401E-8CD2-AD80B2BFEDC1 Q38543425-FF746385-805A-4D12-B13B-3A0E1B94A3E7 Q38993412-17F33A96-82B4-4DC2-89FC-8D605385D525 Q39172346-58291CBE-1905-4DE4-91CF-A6E8C6F8FB95 Q40716131-27B0F9C7-6D37-4D7A-83B8-EC5071E00283 Q42038712-68126099-E856-42F3-AB7B-41C6576623F3 Q42283377-0400FC48-DAF0-4034-98C2-DB023806876A Q43030314-F2B8ED18-A16D-4BF7-9355-6A3B52BA9EB1 Q44313632-626BD675-F9A6-4016-AC39-CE9A321A83F2 Q46619541-30411FA3-E928-4531-A8F9-916D95E45799 Q46850433-0F92AB2F-DC4A-42D4-A0A9-ACB452E83312 Q47116927-1A3AE805-1CF7-4EF0-8720-922BC0E7974F Q47590416-558B7192-081B-42EE-BE03-79E9B4023C4E Q48097450-5593656F-DB27-49D6-B046-32232E3244BB Q48595869-C67BB9C3-0E67-4110-B15C-0B88E0A0B829 Q48962618-97921941-474C-4E4E-AAD5-597479675497 Q55243030-B54EA8BB-4383-4071-925A-52185B5E6D15 Q56422855-BB9D80F4-C864-42A6-8F16-DBE032C422FD Q56978872-CD8E2A17-B62C-4DF0-AEFB-31A56D1C5BB1

P2860

Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.

http://www.wikidata.org/entity/Q31029305

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Amyloidogenicity and clinical ...... tations in apolipoprotein A-I.

@ast

Amyloidogenicity and clinical ...... tations in apolipoprotein A-I.

@en

type

label

Amyloidogenicity and clinical ...... tations in apolipoprotein A-I.

@ast

Amyloidogenicity and clinical ...... tations in apolipoprotein A-I.

@en

prefLabel

Amyloidogenicity and clinical ...... tations in apolipoprotein A-I.

@ast

Amyloidogenicity and clinical ...... tations in apolipoprotein A-I.

@en

P1433

Q31029305-AB33F142-2960-426E-AB0E-CAEB80B16BA3

P1476

Q31029305-5318DDC8-CCE9-431C-9EE1-BD9EA5995241

P2093

Q31029305-279F4411-2634-435B-9B56-533F32DAEC96

Q31029305-30DF3DD8-C1B4-4B2A-B912-BA321870C840

Q31029305-41D039E4-029E-477C-96CD-ABE3DCFA85B2

Q31029305-4F191222-B4F4-4E14-8F06-CD3773BAB11E

Q31029305-59404CFD-8B6F-4ADC-8E38-995C94B6D4D4

Q31029305-702F2B28-759E-4C54-9BDB-9FBBF4EA5D1F

Q31029305-8AD09DB0-37E5-4FFE-B5CF-1012A6742125

Q31029305-9BB2A53E-8D46-4E0D-A2AF-9B4D3E89EAC7

Q31029305-AA62D5CF-0BB4-424A-ABBE-A373559664E7

Q31029305-B2E44F21-DEC9-4614-909A-1619511EC72A

P2860

Q31029305-05DF3C1A-72BF-40FD-92AE-C47C7705A76D

Q31029305-0AB60ABD-9353-45C2-ABFB-5F6318A2ABBA

Q31029305-1039923E-9336-4CC3-8381-5AE511931A7F

Q31029305-296CD016-1A8E-4B56-96CF-392A408CC1C1

Q31029305-2B5E3952-1F7E-4D5D-88E9-C45AA8AAB336

Q31029305-2E8BF9AB-D287-4F47-A340-36B1EE29E863

Q31029305-2FD417AE-AA83-4644-9003-86A8769ACC22

Q31029305-3066FBF7-7990-4D1C-B8B7-5D1F3697DAD7

Q31029305-30A85E7E-8E57-43BB-ADD7-BEA22F906B8B

Q31029305-34DCAAD7-2731-40CA-9BAC-289A96C47D7F

P304

Q31029305-F639E10F-BE61-40F6-9654-8D108A98526C

P31

Q31029305-D376AFE9-795D-4FE6-87CF-5EC9D8AD8FA6

P356

Q31029305-39151689-3605-4A38-9052-16FD5D432B26

P407

Q31029305-E32DD775-7EAD-4A89-8DED-5706570ED96E

P433

Q31029305-DB76B2E4-C0A6-4CEE-9A71-C9F243AACA7C

P478

Q31029305-87211765-79AC-43DE-A4E5-734EE9797FA7

P50

Q31029305-2F04543E-2193-41E8-9D3F-F1398A08BC2F

P577

Q31029305-B422A9BA-58C8-4303-8B3A-E5C6C4B08646

P5875

Q31029305-007021FA-9E33-4A28-8DE5-9C9F7FF8F777

P698

Q31029305-B3B7E41E-BAAC-4B45-9A8A-912332EC61E6

P932

Q31029305-3D49756B-DAB4-4471-8A42-6C1FA0B04FB5

P356

J.AJPATH.2011.06.024

P1433

The American Journal of Pathology

P1476

Amyloidogenicity and clinical ...... tations in apolipoprotein A-I.

@en

P2093

Ahmet Dogan

http://www.w3.org/2001/XMLSchema#string

Ashutosh D Wechalekar

http://www.w3.org/2001/XMLSchema#string

Dorota Rowczenio

http://www.w3.org/2001/XMLSchema#string

Janet A Gilbertson

http://www.w3.org/2001/XMLSchema#string

Jason D Theis

http://www.w3.org/2001/XMLSchema#string

Jenny H Pinney

http://www.w3.org/2001/XMLSchema#string

Julian D Gillmore

http://www.w3.org/2001/XMLSchema#string

Julie A Vrana

http://www.w3.org/2001/XMLSchema#string

Philip N Hawkins

http://www.w3.org/2001/XMLSchema#string

Prayman T Sattianayagam

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis

Variant apolipoprotein AI as a major constituent of a human hereditary amyloid

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Hereditary renal amyloidosis with a novel variant fibrinogen.

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.

Human lysozyme gene mutations cause hereditary systemic amyloidosis.

Prevalence of monoclonal gammopathy of undetermined significance.

APOA1 related amyloidosis: a case report and literature review.

P304

1978-1987

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJPATH.2011.06.024

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P50

Helen J Lachmann

P577

2011-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51551491

http://www.w3.org/2001/XMLSchema#string

P698

21820994

http://www.w3.org/2001/XMLSchema#string

P932

3181365

http://www.w3.org/2001/XMLSchema#string